Biologics: Hope, Market Pressures, Evidence, Guidelines, and Equipoise

Ronald A. Navarro, MD, FAAOS, FAOA; Gary E. Friedlaender, MD, FAAOS, FAOA, FORS

Through the application of rigorous scientific methodology, evidence-based practice, and advances in safe and effective technology, many important new solutions to serious health issues are being addressed with orthobiologic products.

AAOS Biologics Initiative Focuses on Advancing Orthobiologics for Better Outcomes

Ryan Pezold, MA, MBa

In the evolving landscape of patient care, biologics are gaining attention as tools that may improve patient outcomes.

AAOS Biologics Symposium Investigates the Present and Future of Orthobiologic Therapies

Terry Stanton

At AAOS’ third annual Biologics Symposium, titled “The Next Generation of Biologics,” hosted on July 12 in collaboration with the Biologic Association, attendees were able to get a “first look” at the next generation of biologics expected to be available and used in orthopaedics over the next several years.

Understanding Regulatory Pathways for Osteobiologic Use in Orthopaedic Surgery

John Cherf, MD, MPH, MBA, FAAOS

Osteobiologics are a subset of biologics that focus on bone regeneration. An estimated 500,000 bone-grafting procedures are performed in the United States annually, and bone is the second most transplanted tissue, second only to blood transfusions.

AAOS Book on Orthobiologics Provides In-depth Insights into an Emerging Field

AAOS recently released a book on orthobiologics, a fast-growing field that uses biologic materials to enhance tissue repair and regeneration.

Exploring Skeletal Stem Cells: Insights and Challenges in Cartilage Regeneration

Cailin Conner

The third annual Biologics Symposium, titled “The Next Generation of Biologics,” took place on July 12 in Washington, D.C., and featured four sessions on regulatory clarity, autologous tissue processing, personalized blood products, and future biologics trends.